// App-Quantinova.ai

8387 : Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg Over 2 years) in Clarity/Clarity Extension: A Post Hoc Analysis of Classic-MS

Researchers

Presenter

  • Gavin Giovannoni

Principal Investigators

  • Thomas P. Leist

  • Aida Aydemir

  • Elisabetta Verdun di Cantogno

Medical Centers

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, PA

Locations

  • United States

  • United Kingdom

Companies

  • EMD Serono Inc.

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • IV

Study Id's

  • NCT03961204

Sponsors

  • Merck KGaA

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved